Business · 10/11/20261 min read
Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
Summary
SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 — Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a…
Original source language: PR Newswire UK — News ReleasesOpen original release →